Sanofi, pCPA sign letter of intent for Dupixent across four indications in dermatology, respiratory care
SNY•Sanofi and pCPA signed a letter of intent covering Dupixent across four dermatology and respiratory care indications, to support patient access through public drug plans in Canada.
1. Letter of intent
Sanofi and pCPA signed a letter of intent covering Dupixent across four indications in dermatology and respiratory care. The agreement is intended to support patient access to the drug through public drug plans in Canada.
